about
Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromeWho is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemiaSalvage second hematopoietic cell transplantation in myelomaPredicting patient survival from microarray data by accelerated failure time modeling using partial least squares and LASSO.Methods for generating paired competing risks dataAutologous is superior to allogeneic hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission.Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: BloodHematopoietic stem cell transplantation for infantile osteopetrosis.Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantationEffect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902)Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTRPatient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902).Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trialIntravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.Weighted comparison of two cumulative incidence functions with R-CIFsmry package.Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting.Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical ConsiderationsPlerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells
P50
Q30371042-B1480E0D-E5E1-4934-9464-8030E242EB7BQ30414156-44FC8081-8053-4918-A61E-D34237578B8AQ30415126-BC7E69E1-4439-436E-BF7B-954F04098A88Q30416452-96CA8BB2-A0BA-4044-8454-0E66A3C8C370Q31109949-C99E78D4-266D-466C-A9CD-83DA16A68D44Q31126215-EB4DAACC-C2C6-4864-8990-DDBED8D5F4EDQ33900803-24FD8E17-8F78-4470-B20B-A757E900EC83Q34175457-70C15252-742A-4D42-A1B4-86B783BF04AFQ34217884-62335F9D-F9B0-4E39-B20D-4031823DA248Q34477968-EFDE9182-EE61-4294-ADC3-BCC145242696Q34649014-4B68F9AB-8408-4E75-9FAC-113D746C20B7Q35197402-BBF09289-1216-4C0E-83C0-BB3097F59865Q36055113-2B45ABE2-F604-47E1-862D-2D612543581EQ36410168-C787B6EB-0C6C-4C3A-A8F9-0391570C575AQ36447635-EA8189D5-560D-4827-8CD7-D08434D641BCQ37021454-14FECE41-9310-438F-AB6A-ED4C60D428ECQ37490480-88B66C06-17D6-4678-8462-7EAAE9F51DFCQ38716340-46C52B39-0971-447C-B894-B38F208E1326Q38827434-C4FC6B53-438F-4D2D-9AB1-7BF1F1CD9B02Q38852431-1BC72275-7198-4B57-BAA2-5C7F7ABD9BBDQ39289941-C438E65C-9C77-4B85-91E7-3A86F40F2625Q39518931-41CDB1EE-C740-4405-AE57-B935C6FD1BF7Q40702849-4F37CD3E-F5C4-4E3F-8066-54EB7FF95B7BQ42175192-98B26EAA-52C2-4352-A19D-6A87EB883186Q42725835-F08475CC-18AF-4886-9404-57CAA8F4A7A5Q50716088-76ABC811-CF8B-4D09-8BC1-D7B4D68FEDD6Q54020641-0DE5FF82-8503-4AFE-B74E-4E49C68A8577Q57161373-7822A6C9-11D5-4BA2-A9E6-D21DF4B0272AQ64073868-F983844E-E093-473C-A998-447ACC6AF9DA
P50
name
Jennifer Le-Rademacher
@en
Jennifer Le-Rademacher
@nl
type
label
Jennifer Le-Rademacher
@en
Jennifer Le-Rademacher
@nl
prefLabel
Jennifer Le-Rademacher
@en
Jennifer Le-Rademacher
@nl